tiprankstipranks
Abbvie (DE:4AB)
NYSE:4AB
Germany Market
4AB
AbbVie
RESEARCH TOOLSreports

AbbVie (4AB) Stock Forecast & Price Target

27 Followers
See the Price Targets and Ratings of:

4AB Analyst Ratings

Moderate Buy
22Ratings
Moderate Buy
16 Buy
6 Hold
0 Sell
Based on 22 analysts giving stock ratings to
AbbVie
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

4AB Stock 12 Month Forecast

Average Price Target

€227.04
▲(27.09% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is €227.04 with a high forecast of €261.96 and a low forecast of €202.18. The average price target represents a 27.09% change from the last price of €178.65.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"155":"€155","262":"€262","181.75":"€181.8","208.5":"€208.5","235.25":"€235.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":261.95683444,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€261.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":227.03902373444444,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€227.04</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":202.1814494,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€202.18</span>\n  </div></div>","useHTML":true}}],"tickPositions":[155,181.75,208.5,235.25,262],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,182.9,188.98129495692308,195.06258991384615,201.14388487076923,207.22517982769233,213.3064747846154,219.38776974153848,225.46906469846155,231.55035965538463,237.63165461230773,243.71294956923077,249.79424452615388,255.87553948307695,{"y":261.95683444,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,182.9,186.2953095180342,189.69061903606837,193.08592855410257,196.48123807213676,199.87654759017096,203.27185710820513,206.66716662623932,210.0624761442735,213.45778566230769,216.85309518034188,220.24840469837608,223.64371421641025,{"y":227.03902373444444,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,182.9,184.3831884153846,185.86637683076924,187.34956524615384,188.83275366153848,190.31594207692308,191.79913049230768,193.28231890769231,194.76550732307692,196.24869573846152,197.73188415384615,199.21507256923076,200.6982609846154,{"y":202.1814494,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":157.248,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.861,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.481,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.053,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.741,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.938,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.267,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":193.415,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":189.612,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":197.943,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.662,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":181.65,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.9,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€261.96Average Price Target€227.04Lowest Price Target€202.18
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on DE:4AB
David Amsellem
Piper Sandler
Piper Sandler
€261.96
Buy
46.63%
Upside
Reiterated
06/23/26
Analysts Conflicted on These Healthcare Names: TScan Therapeutics (NASDAQ: TCRX), Exelixis (NASDAQ: EXEL) and AbbVie (NYSE: ABBV)
Citi Analyst forecast on DE:4AB
Geoff Meacham
Citi
Citi
€202.18
Hold
13.17%
Upside
Reiterated
06/23/26
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (NASDAQ: TENX), Abbott Laboratories (NYSE: ABT) and AbbVie (NYSE: ABBV)
Wells Fargo Analyst forecast on DE:4AB
Mohit Bansal
Wells Fargo
Wells Fargo
€228.55
Buy
27.93%
Upside
Assigned
06/23/26
AbbVie (ABBV) Gets a Buy from Wells Fargo
Scotiabank Analyst forecast on DE:4AB
Louise Chen
Scotiabank
Scotiabank
€246.13
Buy
37.77%
Upside
Reiterated
06/23/26
Scotiabank Keeps Their Buy Rating on AbbVie (ABBV)
TD Cowen Analyst forecast on DE:4AB
Nicholas Lorusso
TD Cowen
TD Cowen
€246.13
Hold
37.77%
Upside
Downgraded
06/23/26
Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (NASDAQ: TSHA) and AbbVie (NYSE: ABBV)
Canaccord Genuity Analyst forecast on DE:4AB
Gary Nachman
Canaccord Genuity
Canaccord Genuity
€232.95→€239.98
Buy
34.33%
Upside
Reiterated
06/23/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Sionna Therapeutics, Inc. (NASDAQ: SION) and Crescent Biopharma (NASDAQ: CBIO)
Bank of America Securities Analyst forecast on DE:4AB
Jason Gerberry
Bank of America Securities
Bank of America Securities
€205.7
Buy
15.14%
Upside
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS), Taysha Gene Therapies (NASDAQ: TSHA) and AbbVie (NYSE: ABBV)
Morgan Stanley Analyst forecast on DE:4AB
Terence Flynn
Morgan Stanley
Morgan Stanley
€237.34→€244.38
Buy
36.79%
Upside
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE) and Insulet (NASDAQ: PODD)
Cantor Fitzgerald Analyst forecast on DE:4AB
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
€210.97
Buy
18.09%
Upside
Reiterated
06/22/26
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Beam Therapeutics (BEAM)
William Blair Analyst forecast on DE:4AB
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
06/22/26
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), MapLight Therapeutics, Inc. (MPLT)
BMO Capital Analyst forecast on DE:4AB
Evan Seigerman
BMO Capital
BMO Capital
€226.79
Buy
26.95%
Upside
Reiterated
06/19/26
AbbVie’s Strategic Pipeline and Immunology Expansion Support Buy Rating, Price Target Reaffirmed at $258
J.P. Morgan Analyst forecast on DE:4AB
Chris Schott
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/19/26
Analysts Conflicted on These Healthcare Names: AbbVie (NYSE: ABBV) and Moderna (NASDAQ: MRNA)
UBS Analyst forecast on DE:4AB
Michael Yee
UBS
UBS
€202.18
Hold
13.17%
Upside
Reiterated
06/19/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Moderna (NASDAQ: MRNA)
Barclays Analyst forecast on DE:4AB
Emily Field
Barclays
Barclays
€241.74
Buy
35.31%
Upside
Reiterated
06/12/26
Analysts Are Bullish on These Healthcare Stocks: C4 Therapeutics (CCCC), AbbVie (ABBV)
Bernstein Analyst forecast on DE:4AB
Courtney Breen
Bernstein
Bernstein
―
Hold
―
Reiterated
06/09/26
AbbVie (ABBV) Receives a Hold from Bernstein
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on DE:4AB
David Amsellem
Piper Sandler
Piper Sandler
€261.96
Buy
46.63%
Upside
Reiterated
06/23/26
Analysts Conflicted on These Healthcare Names: TScan Therapeutics (NASDAQ: TCRX), Exelixis (NASDAQ: EXEL) and AbbVie (NYSE: ABBV)
Citi Analyst forecast on DE:4AB
Geoff Meacham
Citi
Citi
€202.18
Hold
13.17%
Upside
Reiterated
06/23/26
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (NASDAQ: TENX), Abbott Laboratories (NYSE: ABT) and AbbVie (NYSE: ABBV)
Wells Fargo Analyst forecast on DE:4AB
Mohit Bansal
Wells Fargo
Wells Fargo
€228.55
Buy
27.93%
Upside
Assigned
06/23/26
AbbVie (ABBV) Gets a Buy from Wells Fargo
Scotiabank Analyst forecast on DE:4AB
Louise Chen
Scotiabank
Scotiabank
€246.13
Buy
37.77%
Upside
Reiterated
06/23/26
Scotiabank Keeps Their Buy Rating on AbbVie (ABBV)
TD Cowen Analyst forecast on DE:4AB
Nicholas Lorusso
TD Cowen
TD Cowen
€246.13
Hold
37.77%
Upside
Downgraded
06/23/26
Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (NASDAQ: TSHA) and AbbVie (NYSE: ABBV)
Canaccord Genuity Analyst forecast on DE:4AB
Gary Nachman
Canaccord Genuity
Canaccord Genuity
€232.95→€239.98
Buy
34.33%
Upside
Reiterated
06/23/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Sionna Therapeutics, Inc. (NASDAQ: SION) and Crescent Biopharma (NASDAQ: CBIO)
Bank of America Securities Analyst forecast on DE:4AB
Jason Gerberry
Bank of America Securities
Bank of America Securities
€205.7
Buy
15.14%
Upside
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS), Taysha Gene Therapies (NASDAQ: TSHA) and AbbVie (NYSE: ABBV)
Morgan Stanley Analyst forecast on DE:4AB
Terence Flynn
Morgan Stanley
Morgan Stanley
€237.34→€244.38
Buy
36.79%
Upside
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE) and Insulet (NASDAQ: PODD)
Cantor Fitzgerald Analyst forecast on DE:4AB
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
€210.97
Buy
18.09%
Upside
Reiterated
06/22/26
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Beam Therapeutics (BEAM)
William Blair Analyst forecast on DE:4AB
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
06/22/26
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), MapLight Therapeutics, Inc. (MPLT)
BMO Capital Analyst forecast on DE:4AB
Evan Seigerman
BMO Capital
BMO Capital
€226.79
Buy
26.95%
Upside
Reiterated
06/19/26
AbbVie’s Strategic Pipeline and Immunology Expansion Support Buy Rating, Price Target Reaffirmed at $258
J.P. Morgan Analyst forecast on DE:4AB
Chris Schott
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/19/26
Analysts Conflicted on These Healthcare Names: AbbVie (NYSE: ABBV) and Moderna (NASDAQ: MRNA)
UBS Analyst forecast on DE:4AB
Michael Yee
UBS
UBS
€202.18
Hold
13.17%
Upside
Reiterated
06/19/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Moderna (NASDAQ: MRNA)
Barclays Analyst forecast on DE:4AB
Emily Field
Barclays
Barclays
€241.74
Buy
35.31%
Upside
Reiterated
06/12/26
Analysts Are Bullish on These Healthcare Stocks: C4 Therapeutics (CCCC), AbbVie (ABBV)
Bernstein Analyst forecast on DE:4AB
Courtney Breen
Bernstein
Bernstein
―
Hold
―
Reiterated
06/09/26
AbbVie (ABBV) Receives a Hold from Bernstein
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

3 Months
Carter GouldCantor Fitzgerald
Success Rate
12/16 ratings generated profit
75%
Average Return
+8.28%
Copying Carter Gould's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +8.28% per trade.
1 Year
Mohit BansalWells Fargo
Success Rate
29/29 ratings generated profit
100%
Average Return
+18.72%
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +18.72% per trade.
2 Years
Carter GouldCantor Fitzgerald
Success Rate
16/16 ratings generated profit
100%
Average Return
+33.73%
Copying Carter Gould's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +33.73% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4AB Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
28
30
45
45
48
Hold
14
14
11
8
12
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
42
44
56
53
60
In the current month, 4AB has received 48 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. 4AB average Analyst price target in the past 3 months is 227.04.
Each month's total comprises the sum of three months' worth of ratings.

4AB Financial Forecast

4AB Earnings Forecast

Next quarter’s earnings estimate for 4AB is €3.29 with a range of €3.24 to €3.44. The previous quarter’s EPS was €2.32. 4AB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 4AB has Performed in-line its overall industry.
Next quarter’s earnings estimate for 4AB is €3.29 with a range of €3.24 to €3.44. The previous quarter’s EPS was €2.32. 4AB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 4AB has Performed in-line its overall industry.

4AB Sales Forecast

Next quarter’s sales forecast for 4AB is €14.68B with a range of €14.49B to €14.81B. The previous quarter’s sales results were €13.13B. 4AB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 4AB has Performed in-line its overall industry.
Next quarter’s sales forecast for 4AB is €14.68B with a range of €14.49B to €14.81B. The previous quarter’s sales results were €13.13B. 4AB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 4AB has Performed in-line its overall industry.

4AB Stock Forecast FAQ

What is DE:4AB’s average 12-month price target, according to analysts?
Based on analyst ratings, Abbvie’s 12-month average price target is 227.04.
    What is DE:4AB’s upside potential, based on the analysts’ average price target?
    Abbvie has 27.09% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Abbvie a Buy, Sell or Hold?
          Abbvie has a consensus rating of Moderate Buy, which is based on 16 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Abbvie’s share price target?
            The average share price target for Abbvie is 227.04. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €261.96 ,and the lowest forecast is €202.18. The average share price target represents 27.09% Increase from the current price of €178.65.
              What do analysts say about Abbvie?
              Abbvie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of Abbvie?
                To buy shares of DE:4AB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.